Recombinant Human C1 Inhibitor

DRUG4 trials

Sponsors

Pharming Technologies B.V.

Conditions

Angioneurotic EdemaGenetic DisordersHereditary Angioedema

Phase 2

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

CompletedNCT00225147

Pharming Technologies B.V.Angioneurotic Edema, Hereditary Angioedema

Start: 2005-07-31End: 2010-01-31Updated: 2013-02-22

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration

CompletedNCT00851409

Pharming Technologies B.V.Genetic Disorders, Hereditary Angioedema

Start: 2009-06-30End: 2010-04-30Updated: 2018-06-26

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

CompletedNCT02247739

Pharming Technologies B.V.Hereditary Angioedema

Start: 2014-12-31End: 2016-09-30Updated: 2017-12-08

Phase 3

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

CompletedNCT00262301

Pharming Technologies B.V.Angioneurotic Edema, Genetic Disorders, Hereditary Angioedema

Start: 2004-06-30End: 2009-10-31Updated: 2012-10-02

Related Papers

Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary Angioedema.

2026-05-20

Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks

Allergy Asthma and Clinical Immunology2025-03-152 citations

Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial.

2017-07-2541 citations

Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks.

2017-03-0912 citations

Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.

2012-06-0136 citations